Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD

Condition:   Squamous Cell Carcinoma of the Head and Neck
Interventions:   Biological: Imprime PGG;   Drug: Pembrolizumab
Sponsors:   Biothera;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified August 2017

http://ift.tt/2uMN6sB